Disease Burden
Disease Burden in Pediatric Atopic Dermatitis Patients and Their Caregivers
Moderate-to-severe atopic dermatitis (AD) imposes a multidimensional disease burden that includes itch, sleep disturbance, mental health impairments, and various multimorbid conditions, all of which can impact quality of life (QOL). Caregivers of pediatric patients with moderate-to-severe AD are also affected by the disease, with reduced QOL, loss of sleep, and increased risk for symptoms of anxiety and depression.1-11
Join Professor Antonella Muraro and learn how AD imposes a multidimensional disease burden in pediatric patients and caregivers.
- Overview of Disease Burden in Pediatric Patients and Caregivers with Atopic Dermatitis (0:12)
Antonella Muraro, EAACI 2022 - Disease Impact on Patients (EPI-CARE) (00:58)
Antonella Muraro, EAACI 2022 - Disease Impact on Caregivers (EPI-CARE) (02:14)
Antonella Muraro, EAACI 2022
References
- Paller AS, et al. J Am Acad Dermatol. S0190-9622(22)00092-5. Epub 2022 Jan 23.
- Ramirez FD, et al. JAMA Pediatr. 2019;173(5):e190025.
- Weidinger S, et al. Poster presented at ESPD, 20–22 May 2022; Munich, Germany.
- Silverberg JI, et al. Poster presented at EADV; September 7–10, 2022; Milan, Italy.
- Shah S, et al. Poster presented at SID Annual Meeting; May 18–21, 2022; Portland, OR, USA.
- Weidinger S, et al. Poster presented at SPD virtual conference; 8–10 July 2021.
- Hou A, Silverberg JI. Pediatr Dermatol. 2021;38(3):606-612.
- Stingeni L, et al. J Asthma Allergy. 2021;14:919-928.
- Barbarot S, et al. J Pediatr. 2022;246:220-226.e5.
- Wu Di, et al. Ann Transl Med. 2021;9(1):40.
- Capozza K, et al. Dermatitis 2020;31(3):223-227.
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority in collaboration with Sanofi and Regeneron, with content provided by Sanofi and Regeneron.
ADVENT is a global medical education program by Sanofi and Regeneron. This Website is intended only for duly authenticated health care professionals.
©2022 Sanofi. All rights reserved. MAT-GLB-2203660 November 2022. V1.0.
Sanofi and Regeneron are committed to providing resources to advance knowledge in areas of unmet medical need among patients with inflammatory and immunologic diseases.